EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia

Rushi Shah, Clarissa Polen-De, Michaela McGree, Angela Fought, Amanika Kumar iD

Current Oncology · 27.10.2023 · 30 (11) · 9501-9513

DOI: 10.3390/curroncol30110688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 27.10.2023. Verfasst von Rushi Shah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Sarcopenia, Ovarian Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single institution were analyzed. Patients with a skeletal muscle index less than 39 cm2/m2 measured on a CT scan were considered sarcopenic. Sarcopenic and non-sarcopenic patients were compared with regard to relative dose intensity (RDI), completion of scheduled chemotherapy, toxicity, and survival. A total of 62 (35.8%) women were sarcopenic. Sarcopenic women were less likely to complete at least six cycles of chemotherapy (83.9% vs. 95.5%, p = 0.02). The mean RDI for both carboplatin (80.4% vs. 89.4%, p = 0.03) and paclitaxel (91.9% vs. 104.1%, p = 0.03) was lower in sarcopenic patients compared to non-sarcopenic patients. Despite these differences in chemotherapy, there was no difference in neutropenia or median overall survival (3.99 vs. 4.57 years, p = 0.62) between the sarcopenic and non-sarcopenic women, respectively. This study highlights the importance of considering lean body mass instead of body weight or surface area in chemotherapy dosing formulas for sarcopenic women with advanced EOC. Further research is needed to optimize chemotherapy strategies based on individual body composition, potentially leading to improved dosing strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaOvarian NeoplasmsHumansFemalePaclitaxelCarboplatinCarcinoma, Ovarian Epithelial

Stichwörter der Autor:innen

adjuvant chemotherapyadvanced epithelial ovarian cancercytoreductive surgeryoverall survivalrelative dose intensitysarcopenia

Substanzen

PaclitaxelCarboplatin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Gynecologic Oncology, Summa Health, Akron, OH 44304, USA.
  • Department of Quantitative Health Sciences, Division Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Obstetrics and Gynecology, Division of Gynecological Surgery, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Amanika Kumar

Förderung

  • NCI NIH HHS

Zitieren

APA

Shah, R., Polen-De, C., McGree, M., Fought, A., & Kumar, A. (2023). Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia. Current Oncology, 30(11), 9501-9513. https://doi.org/10.3390/curroncol30110688

Vancouver

Shah R, Polen-De C, McGree M, Fought A, Kumar A. Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia. Current Oncology. 2023;30(11):9501-9513. doi:10.3390/curroncol30110688

BibTeX
@article{Shah2023,
  author = {Shah, Rushi and Polen-De, Clarissa and McGree, Michaela and Fought, Angela and Kumar, Amanika},
  title = {Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {11},
  pages = {9501--9513},
  doi = {10.3390/curroncol30110688}
}
Kostenlos starten →